Combination extends median endometrial-cancer survival by 11.5 months

The global Phase 3 DUO-E trial enrolled 718 patients with advanced or recurrent endometrial cancer. Compared with chemotherapy followed by placebo, chemotherapy plus durvalumab followed by maintenance durvalumab and olaparib produced median overall survival of 51.1 months, an 11.5-month extension. At 36 months, 63.4% of patients in that arm were alive versus 52% in the control arm. Researchers also observed benefit among the majority with mismatch-repair-proficient tumors, who historically have fewer effective options, and reported no new safety signals in this analysis. The findings were presented at ESMO 2026 and the study was funded by AstraZeneca. Final overall-survival analysis continues, so this is an important Phase 3 result, not a guaranteed outcome for every patient or an automatic new treatment standard.